Author: Allegro Ophthalmics, LLC

WAILEA, Hawaii — At Retina 2018, Peter K. Kaiser, MD, discusses research targeting different pathways for treating diabetic macular edema.

To view the video, please visit Healio.com/OSN: “Research targets different pathways for treating DME”

WAILEA, Hawaii — At Retina 2018, Pravin U. Dugel, MD, discusses the ongoing clinical trials for Allegro’s anti-integrin therapy in the treatment of retinal disease.

To view the video, please visit Healio.com/OSN: “Anti-integrin trials in line with scientific expectations”

In a phase 2b study, ALG-1001 showed additional efficacy in patients who had plateaued on chronic anti-VEGF therapy.

To read the full article please visit Retina Today: “The Latest Data on Anti-Integrin Therapy for Patients with DME”

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Baruch D. Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at UC Irvine, discusses results from the DEL MAR trial of Luminate (Allegro) for the treatment of diabetic macular edema.

To view the video, please visit Healio.com/OSN: “Luminate after Avastin shows early promise for treating diabetic macular edema”

Baruch D. Kuppermann, MD, PhD, discusses Novel anti-integrin therapy at the Ophthalmology Innovation Summit @AAO 2017.

To view the video, please visit EyeWorld Video Reporter: “Novel anti-integrin therapy”

Vicken Karageozian, MD, discusses results of a phase-2 trial of an anti-integrin drug for diabetic macular edema.

To view the video, please visit EyeWorld Video Reporter: “Allegro at the Ophthalmology Innovation Summit @AAO 2017”

Anti-integrin therapy addresses pathophysiology; targets early point in pathogenic pathway.

To read the full article please visit Ophthalmology Times: “Novel DME treatment derives from multimodal activity”

ALG-1001 (Luminate^®, Allegro Ophthalmics), a first-in-class integrin peptide therapy, met the primary endpoint of vision non-inferiority to bevacizumab (Avastin, Genentech Inc.), an anti-vascular endothelial growth factor therapy (anti-VEGF), with 12-week durability in a population of patients with mostly chronic diabetic macular edema (DME).

ALG-1001 seems to be a strong player with different mechanisms of action that benefit patients who have been receiving chronic anti-VEGF therapy and those who are treatment naïve.

To read the article, please visit Ophthalmology Times: “ALG-1001: Turning off the machinery of angiogenesis”